A novel model of controlling PD-L1 expression in ALK<sup>+</sup> anaplastic large cell lymphoma revealed by CRISPR screening.
Zhang, Jing-Ping; Song, Zhihui; Wang, Hong-Bo; Lang, Lang; Yang, Yuan-Zhong; Xiao, Wenming; Webster, Daniel E; Wei, Wei; Barta, Stefan K; Kadin, Marshall E; Staudt, Louis M; Nakagawa, Masao; Yang, Yibin.
; 134(2): 171-185, 2019 07 11.
Artigo em Inglês | MEDLINE | ID: mdl-31151983
Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
Non-Coding RNA Networks in ALK-Positive Anaplastic-Large Cell Lymphoma.
The biology and management of systemic anaplastic large cell lymphoma.
Recurrent <i>MSC</i> <sup>E116K</sup> mutations in ALK-negative anaplastic large cell lymphoma.
The Long Non-Coding RNA MIR503HG Enhances Proliferation of Human ALK-Negative Anaplastic Large-Cell Lymphoma.
Partial deletion of the ALK gene in ALK-positive anaplastic large cell lymphoma.
Drug-resistance mechanisms of three mutations in anaplastic lymphoma kinase against two inhibitors based on MM/PBSA combined with interaction entropy.
ALK-positive anaplastic large-cell lymphoma with primary bone involvement: A rare case and review of the literature.
Disease site as a determinant of survival outcome in patients with systemic anaplastic lymphoma kinase positive anaplastic large cell lymphoma with extranodal involvement: an analysis of 1306 cases from the US National Cancer Database.
Anaplastic large cell lymphoma in paediatric and young adult patients.